Woojin B&G Achieves Research Results in Porcine Respiratory Virus Vaccine

Woojin B&G, an animal pharmaceutical company, has achieved significant research results in the 'porcine respiratory virus vaccine (PCV2d)' market, which is monopolized by multinational corporations with over 90% market share in Korea.

According to Woojin B&G on June 25, four research achievements, including a study on its proprietary ELISA verification system developed for quantitative immunological evaluation of its PCV2d vaccine, have been published in international academic journals.

This research is being highlighted as a representative case that combines the analytical technology and immunological evaluation expertise of Woojin B&G's Central Research Institute and Vaccine Research Institute through their collaboration.

To accurately measure antibody titers in the immune response to the porcine circovirus and Mycoplasma combination vaccine, the company optimized antigen coating, blockers, and specificity verification using rabbit antisera produced in-house, and secured sensitivity, reproducibility, and linearity. In addition, it experimentally demonstrated the correlation between guinea pig and pig sera, which is being recognized as presenting the possibility for scientific improvement of the existing national approval standards.

Woojin B&G's Immunis® DMVAC is expected to serve as a strong competitor in the domestic porcine circovirus-Mycoplasma vaccine market, which is worth approximately 40 billion KRW and is almost monopolized by multinational corporations, based on its high level of technology.

Currently, Immunis® DMVAC has completed development and is undergoing product approval. With the recognition of this ELISA verification research in academic journals, it is expected to bolster the verification phase.

In addition to this PCV2d in-house ELISA study, Woojin B&G is also accumulating scientific evidence by preparing publications on major disease vaccines under development, such as the porcine influenza virus vaccine and the porcine edema disease vaccine.

Through these efforts, the company aims to objectively verify field efficacy and secure reliability for national approval standards and entry into the global market.

A Woojin B&G representative stated, "The PCV2d in-house ELISA study is a case of establishing a scientific quality evaluation system, and we expect it to contribute to future improvements in national standards. We will expand scientific verification through publications on various livestock species and diseases to strengthen our technological competitiveness in the global vaccine market."